The new flow sensors, BioPAT Flow, enable precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.
Sartorius Stedim Biotech (SSB), supplier of pharmaceutical and biotech equipment, has entered into an agreement with em-tec, a flow measurement company that specializes in non-invasive flow engineering solutions for blood vessels and flexible tubing. This type of technology is used in the biopharmaceutical industry in process steps requiring accurate measurement of flow rates and mass balances, in particular in downstream processes, such as virus inactivation, ultrafiltration, and diafiltration.
Under the terms of the agreement, em-tec’s technology will be used to jointly develop single-use components, such as FlowTube. SSB will hold exclusive marketing rights to these applications and will distribute them as private label products under the brand name, BioPAT Flow.
SSB is constantly working to expand its process analytics portfolio in the sensor technology to enable non-invasive real-time measurement of critical process parameters, such as pH, dissolved oxygen, temperature, glucose, lactate and biomass. The new flow sensors, BioPAT Flow, enable precise, reproducible data to be collected on flow rates and mass balances without coming in contact with the medium during measurement.
Stefan Schlack, senior vice president of marketing at SSB, commented in a press release, that the sensors make downstream unit operations more intelligent and increase the level of automation. He added that these sensors are useful tools for designing robust biopharmaceutical processes and further optimizing them.
Dr. Hannspeter Schubert, managing director of em-tec, stated that his company is pleased to have SSB opting for its technology of non-invasive flow rate measurement. “The use of our sensors in fully integrated, automated bioprocesses represents an ideal application field and an innovative technological advance for us.”
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.